DOCSLIB.ORG

ANNUAL REPORT 2015-16 Contents

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ANNUAL REPORT 2015-16 Contents ANNUAL REPORT 2015-16 Contents Corporate Information 02 The Story in Numbers 04 Thyrocare – A Snapshot 06 Board of Directors 12 Chairman's Review 14 `LHYZVM Translating Vision Into Reality 18 Translating Strategies Into Volumes 20 Translating Technologies to Gain Velocity 22 Accelerating Through Brands 24 Nurturing Intellectual Capital 26 Board's Report 27 Corporate Governance Report 49 CEO Certificate on Code of Conduct 58 CEO and CFO Certification 58 Management Discussion & Analysis 59 Financial Statements 81 Standalone Financial Statements 86 Consolidated Financial Statements 119 16th Annual General Meeting Notice 157 Thyrocare Technologies Limited 3H[L:T[:\TH[OP=LS\THUP -VYTLY5VU,_LJ\[P]L+PYLJ[VY;O`YVJHYL;LJOUVSVNPLZ3PTP[LK (December 17, 1960 to February 13, 2016) Your life has been an inspiration to all of us with the passion and focus you demonstrated in every task that you undertook. We remain thankful for your invaluable contribution towards the growth of the Company. While you may not be with us today, your memories shall always remain in our hearts as a cherished treasure. We will continue to move steadfastly towards achieving the higher goals you had set for our Company, your vision and values guiding us all at Thyrocare. 0UMVUKTLTVY` From the entire team of Thyrocare *VYWVYH[L6]LY]PL^ Statutory Reports Financial Statements Corporate Information 9LNPZ[LYLK6MÄJL Thyrocare Technologies Limited D/37-1, TTC Industrial Area, MIDC Turbhe, Navi Mumbai - 400 703. Tel: +91 22 2762 2762 | Fax: +91 22 2768 2409 Website: www.thyrocare.com | E-mail: [email protected] Corporate Identity Number: U85110MH2000PLC123882 *VYWVYH[L6MÄJL Thyrocare Technologies Limited D/37-3, TTC Industrial Area, MIDC Turbhe, Navi Mumbai - 400 703. 9LNPZ[YHY :OHYL;YHUZMLY(NLU[ Link Intime India Private Limited C-13, Pannalal Silk Mills Compound, L.B.S. Marg, Bhandup (West) Mumbai - 400 078, Maharashtra, India. Tel: +91 22 6171 5400 | Fax: +91 22 2596 0329 Website: www.linkintime.co.in E-mail: [email protected] )HURLYZ Axis Bank Limited IDBI Bank Limited ICICI Bank Limited Citibank :[H[\[VY`(\KP[VYZ B S R & Co. LLP, Chartered Accountants 5th Floor, Lodha Excelus, Apollo Mills Compound N.M. Joshi Marg, Mahalaxmi, Mumbai - 400 011. Tel.: +91 22 4345 5300 | Fax: +91 22 4345 5399 02 Thyrocare Technologies Limited It has been 20 years since we commenced operations as a healthcare service provider with a vision. (]PZPVU that focussed on providing wellness and preventive diagnostic services to the common man at the most affordable rates; enabled us to disrupt the dynamics of the industry through focus on high volumes, low pricing, franchising concept, use of advanced technologies and speed of delivery; propelled us to become the undisputed leader in the segment; contributed to our exponential growth during these years. However, at Thyrocare, our vision is not just about the destination that we have arrived at. It is about the journey that we made to come here, the path that we took and the challenges we faced and more importantly, it is about our passion to become the world's largest preventive care laboratory that provides world-class quality to the masses. Annual Report 2015-16 03 *VYWVYH[L6]LY]PL^ Statutory Reports Financial Statements The story in numbers Income from EBITDA operations growth growth 30.6% 28.8% Over 2014-15 Over 2014-15 CAGR FY12-16 CAGR FY12-16 PAT Samples growth growth 20.8% 27.5% Over 2014-15 Over 2014-15 CAGR FY12-16 CAGR FY12-16 Total investigations Total assets growth growth 28.6% 41.3% Over 2014-15 Over 2014-15 CAGR FY12-16 CAGR FY12-16 Promoters' Earnings per holding share (`) as on as on March 31, 2016 March 31, 2016 04 Thyrocare Technologies Limited INCOME FROM OPERATIONS (` in Mn) EBIDTA (` in Mn) FY16 FY15 FY14 FY13 FY12 FY16 FY15 FY14 FY13 FY12 PAT (` in Mn) NET WORTH (` in Mn) FY16 FY15 FY14 FY13 FY12 FY16 FY15 FY14 FY13 FY12 SAMPLES PROCESSED (in ‘000) TOTAL INVESTIGATIONS (in ‘000) FY16 FY15 FY14 FY13 FY12 FY16 FY15 FY14 FY13 FY12 Annual Report 2015-16 05 *VYWVYH[L6]LY]PL^ Statutory Reports Financial Statements Thyrocare - a snapshot Thyrocare is a reputed and reliable pan-India diagnostic solutions provider, offering high quality services at affordable prices. Steered by deep domain expertise and well-established competencies, the Company has emerged among India’s fastest growing and leading companies in the healthcare sector. A combination of strong vision, disruptive business ideas, and sharp entrepreneurial skills has spearheaded the success of the Company. The Company positions itself as a front-end laboratory that uses state-of-the-art equipment with a robust back-end IT system to manage its extensive volume of business and provide value- added services to customers. Driven by a team of skilled and dedicated employees, the Company continues to reinforce the trust and belief reposed by its expanding customer base. 06 Thyrocare Technologies Limited 3,.(*@ p Founded in 1996 by the visionary Dr. A Velumani (an ex-scientist at Bhabha Atomic Research Centre) p Currently valued at more than USD 400 million p Private equity investors include Agalia Private Limited, Samara Capital, Norwest Venture Partners and Emerging India Fund p Listed in the National Stock Exchange and Bombay Stock Exchange =0:065 p Thyrocare should serve to 50% of world's population, 50% of their diagnostic needs at 50% of the costs p Thyrocare should be the biggest client for top 20 diagnostic manufacturing companies in the globe 40::065 p Being in the healthcare industry, it is the patient who is both our primary customer and concern p Ensuring that the right value is given at the right time to the right patient is the test we undergo everyday successfully Annual Report 2015-16 07 *VYWVYH[L6]LY]PL^ Statutory Reports Financial Statements 2,@6--,905.: The Company leveraged its experience and expertise in the diagnostic testing industry to develop the brand. It took this initiative a step further by creating various brands to provide a wide range of tests and profiles for testing. These brands include: Services offered +PHNUVZ[PJ;LZ[PUN Metabolic disorders and Thyroid testing Services offered >LSSULZZHUK7YL]LU[P]L*HYL Liver, cholesterol, kidney, thyroid, iron deficiency, testosterone, cardiac markers, pancreas, electrolytes, arthritis, folic acid, toxic elements, diabetic screening, complete hemogram and vitamin deficiency profile Services offered *HUJLYTVUP[VYPUN Full body and Brain scans Services offered >H[LY;LZ[PUN Physical and chemical contaminants, elements, microbiology, pesticides and volatile organic compounds testing (**9,+0;(;065: ISO 9001:2008 NABL (National CAP (College of American Pathologists) Accreditation Board for Testing and Calibration Laboratories) 08 Thyrocare Technologies Limited .,6.9(7/0*:79,(+ Headquartered in Navi Mumbai Six operational Regional Processing Laboratories (RPLs) in New Delhi, Bhopal, Kolkata, Hyderabad, Coimbatore and Bengaluru Note: Map not to scale Thyrocare is driven by the goal to make available affordable diagnostic services a reality for every Indian. As of date, the network includes presence of 1,041 authorised service providers (ASPs) in 566 cities scattered across the country, to cater to the requirements of clients even in remote areas of the country. The Company is continually exploring new formats to further expand its business model. p Headquartered in Navi Mumbai (India) with a state-of-the-art fully automated 200,000 sq. ft. Central Processing Laboratory (CPL) having the most advanced testing equipment p Six operational Regional Processing Laboratories (RPLs) in New Delhi, Bhopal, Kolkata, Hyderabad, Coimbatore and Bengaluru 05-9(:;9<*;<9,(5+;,*/5636.@7(9;5,9: Thyrocare houses some of the most advanced testing and automation equipment, which are either developed in-house with the assistance of third party vendors as per specific requirements or procured from leading international technology suppliers like Siemens, Transasia Bio Medicals and Roche Diagnostics India. Annual Report 2015-16 09 *VYWVYH[L6]LY]PL^ Statutory Reports Financial Statements 1996 2001- 04 p Commenced operations under the name p Received ISO and CRISIL certification Thyrocare Diagnostics Pvt. Ltd. with only p Entered into agreement with Bayer seven tests in its menu Diagnostics (presently Siemens) for instrument supply and launched Thyroid tests by CLIA technology p Undertook various laboratory upgradation that include bi-directional interfacing system, unique barcoding system and procurement of advanced instruments 43 20cr 1997- 2000 (]LYHNL/LHK ;\YUV]LY p Introduced various new tests, upgraded *V\U[ systems and infrastructure p Moved to a 2,500 sq. ft. premises and added about 50 service providers to its network p Thyrocare Technologies Limited is incorporated 2005-2008 p Increased test menu to 50 and upgraded p Received accreditation from ‘NABL' infrastructure with ERP software and p Launched a comprehensive preventive care automation system profile under the brand Aarogyam p Launched integrated air-cargo logistics p Launched Direct Selling Associates (DSA) system with email reporting facility model for promoting preventive care profile p Launched the first monthly magazine in p Issued fully convertible debentures diagnostic industry aggregating ` 250 million to BCCL p Received accreditation from ‘CAP' p Shifted to a 50,000 sq. ft. Central Processing Laboratory with modern infrastructure p Introduced SugarScan glucose monitor for 2009-2010 Point of Care
Load more

Recommended publications
  • Buy Back Announcement
    Thyrocare Think Thyroid. Thin>< Thyrocare. I Date: September I I. 2018 The SecretarY The Secretary �ational Stock Exchange of India Limited. Bombay Stock Exchange Limited Exchange Plaza. C-l. Phiroze Jeejeebhoy To"ers. 13lock-G. Sandra Kurla Complex. Dalal Street 13andra ( East) Mumbai -WO 023 Mumbai -lO0 051 Security Code : 539871 Security ID : THYROCARE Dear Sirs. Subject: Furnishing the Public Announcement for the Buyback of Equity shares through Open :vtarket in terms of the pro,·isions of Companies Act, 2013, as amended and SEBI (Buy Back of Securities) Regulations, 1998, as amended (the "Buyback Regulations") This is in fu11hcrance to. ( i) our intimation letter dated July 28. 20 I 8. regarding convening of our Board Meeting to apprO\'e the bu: back. (ii) our letter dated August 4.2018. informing the outcome of our Board �lceting held on the same date that approved the buyback of our equity shares from the open market th1w1gh thl.'. swck exchange mechanism: and (iii) our shareholders meeting dated September I, 2018. appnn·ing the bu: back. \\' e enclose here" ith a copy of the Pub Iic /\nnouncement dated September I l. 2018 (the ··Public .-\nnounccmenf") for the buyback being made pursuant to the pro\·isions of the Buyback Regulations. as amended. In compliance,, ith the requirements of the Buyback Regulations. the Public Announcement \\'as released for publication on September I l. 2018 in the follo"·ing ne" spapers: Newspaper Language Editions Financial Ex ress En!!lish j All Jansatta Hindi /\II Mumbai Lakshadee :Vtarathi All Kindl: take the ablwe l1n record. Thanking you. Your:- faithful!:.
    [Show full text]
  • Transcript of the Earnings Call Held on Thursday, February 04, 2021 at 05.00 P.M
    Thyrocare® The Trust. The Truth. February 20, 2021 To, National Stock Exchange of India Limited BSE Limited Exchange Plaza Phiroze Jeejeeboy Towers Sandra Kurla Complex, Dalal Street, Sandra (E), Mumbai - 400 051 Mumbai- 400 00 I Dear Sir/Madam, Sub: Disclosure of information under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. --o-- Pursuant to Regulation 30 of SEBJ (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are filing herewith the transcript of the Earnings Call held on Thursday, February 04, 2021 at 05.00 P.M. local time, post declaration of the Company's unaudited financial results (Stand-alone and Consolidated) for Quarter /Nine Months ended December 3 I, 2020. This transcript is also made available at our website. Dr. A. Velumani, Chairman & Managing Director, Mr. Arindam Haldar, CEO, Mr. A. Sundararaju, CFO & Executive Director, Mr. Sachin Salvi, Vice-President- Finance, represented the Company. Yours Faithfully, For Thyrocare Technologies Limited, Ramjee Dorai Company Secretary and Compliance Officer Thyrocare Technologies Limited 9 0-37/1, TTC MIDC, Turbhe, Navi Mumbai -400 703, India (9 022- 3090 0000 / 4125 2525 � [email protected] @) www.thyrocare.com (CIN: L85110MH2000PLC123882) “Thyrocare Technologies Limited Q3FY21 Earningss Conference Call hosted by Nomura Securities” February 04, 2021 MANAGEMENT: DR. A. VELUMANI, PH.D. – CHAIRMAN & MANAGING DIRECTOR, THYROCARE TECHNOLOGIES LIMITED MR. ARINDAM HALDAR – CHIEF EXECUTIVE OFFICER, THYROCARE TECHNOLOGIES LIMITED MR. A. SUNDARARAJU – CHIEF FINANCIAL OFFICER & EXECUTIVE DIRECTOR, THYROCARE TECHNOLOGIES LIMITED MR. RAMJEE DORAI – COMPANY SECRETARY, THYROCARE TECHNOLOGIES LIMITED MR. SACHIN SALVI – VICE PRESIDENT, FINANCE, THYROCARE TECHNOLOGIES LIMITED DR. CAESAR SENGUPTA – VICE PRESIDENT, OPERATIONS, THYROCARE TECHNOLOGIES LIMITED MODERATOR: MR.
    [Show full text]
  • Thyrocare Think Thyroid
    Thyrocare Think Thyroid. Think Thyrocare. I Date: September 06, 2018 To To The Manager The General Manager National Stock Exchange of India Limited BSE Limited Corporate Communication Department Dept. of Corporate Sen·ices Exchange Plaza. Bandra Kurla Complex Phirozc Jeejeebhoy TO\\·ers I Bandra (E). Mumbai - -WO 051 Dalal Street. Mumbai - 400 001 Dear Sir/ :\1adam Sub.: Submission of Annual Report for Financial vear 2017-18 Ref.: Svmbol: THYROCARE; Scrip Code: 539871 ,\s informed earlier to you. our I 8th Annual General Meeting. which was schedule to be held on August 11. 2018. \\·as postponed and held on September 01. 2018. at 03.00 p.m. at Hotel Yogi tvtidto\\'n. Plot No. DX-12. TTC Industrial Area. Mumbai-Pune Road. Turbhe. Nm·i \tumbai - -+00705. In this regard. as required under Regulation 3-+ or the SEBI (Listing Obligations and Disclosure Requirements). Regulations 2015. \\·e are fo1warding a copy of the Annual Report for the financial year 2017-18 \\'hich \\'as duly approved and adopted by the members along \\·ith a copy of re\'ised AGM oticc issued to the Members .. Kindly take the same on your record. Thanking You. Yours faithfulh· For Thyrocarc Technologies Limited Ramjce Dorai Company Secretary and Compliance Officer 1 hyroc.arP Tect1nolog1e� L1r11 ted 9 D-37/1, TTC MIDC, Turbhe, Navi Mumbai - 400 703, India © 022- 3090 0000 / 4125 2525 � [email protected] «ID www.thyrocare.com (CIN . L85110MH2000PLC123882) I 22years of Journey in Ayushman Bharat Annual Report 2017-18 *Map not to scale. For illustrative purposes only.
    [Show full text]
  • Board's Report
    Corporate Overview Statutory Reports Financial Statements BOARD’S REPORT ANNEXURE 2 REPORT ON CSR ACTIVITIES 1 A brief outline of the company’s CSR policy, including The Company’s CSR Policy is based on the principle of extending overview of projects or programmes proposed to be support to the underprivileged segments of the Society and to render undertaken and a reference to the web-link to the CSR policy service to achieve selected goals for the common benefit of the entire and projects or programmes: society. The Company has identified four thrust areas for implementation of its CSR Policy, viz. (i) Environment-oriented (ii) Society-oriented (iii) Education-oriented and (iv) Health-care oriented. CSR Policy may be viewed at the Company’s website, “www.thyrocare. com” 2 The composition of the CSR Committee: The Company has a CSR committee of directors comprising of - Mr. Gopalkrishna Shivaram Hegde, Independent Director-Chairman - Mr. Vishwas Kulkarni, Independent Director- Member - Mr. A. Sundararaju, Executive Director & CFO- Member `in millions 3 Average net profit of the Company for the three financial 757.63 years: 4 Prescribed CSR expenditure at 2% of the above amount 15.15 5-a Total amount spent during the year 2016-17 13.51 5-b Amount unspent 1.64 5-c Manner in which the amount spent during the financial year Mentioned in Annexure Attached 6 In case the company has failed to spend the two per cent of The balance amount, which could not be spent pending identification the average net profit of the last three financial years or any of another suitable project, will be spent in the financial year 2017-18 part thereof, the company shall provide the reasons for not spending the amount in its Board report.
    [Show full text]
  • Sr. No. Folio No. Name Adress-1 Address2 Address-3 City PIN
    CIN No. L85110MH2000PLC123882 Name of the Company Thyrocare Technologies Limited Nature of Dividend 2015-16 Final Declaration Date 26-09-2015 Amount of Dividend Rs. 205755/- Sr. No. Folio No. Name Adress-1 Address2 Address-3 City PIN SHARES Dividend Amount 1 1202650000027677 RUMA SARKHEL CONTRACTOR PARA BIRMITRAPUR BIRMITRAPUR 10 25 2 IN30154932235443 NARENDER KUMAR KHANDELWAL 867 JOSHI ROAD FAIZ ROAD KAROL BAGH NEW DELHI NEW DELHI 110005 24 60 3 IN30154933989494 ANKUR GUPTA 2/7 ROOP NAGAR DELHI GURGAON 110007 33 82.5 4 IN30154935668580 RITESH DAMANI H N B-48 1ST FLOOR DERAWAL NAGAR MODEL TOWN DELHI NEW DELHI 110009 100 250 5 IN30154937986441 NEERAJ KUMAR AGRAWAL 149F/F DHAKKA VILL KW CAMP DELHI MIRZAPUR 110009 50 125 6 IN30154950225880 HARSH GOGIA 2717 MUKHERJEE NAGAR DELHI NEW DELHI 110009 33 82.5 7 IN30154950715714 SHANTA DATTA ED-10 BLOCK-ED INDER PURI DELHI DELHI 110012 33 82.5 8 IN30154938745009 VINEET HANDA I-4 I-BLOCK KIRTI NAGAR DELHI NEW DELHI 110015 33 82.5 9 IN30154936591047 VIKRANT HANDA I-4 I-BLOCK KIRTI NAGARDELHI NEW DELHI 110015 33 82.5 10 IN30094010192125 SHARDA KATHURIA G-19 BALI NAGAR NEW DELHI NEW DELHI 110015 20 50 11 IN30154951504266 ANUBHA AGRAWAL H NO 82 3RD FLR VIKRAM SHEELA APTS IIT CAMPUS HAUZKHAZ NR NEW CAMPUSDELHI NEW DELHI 110016 10 25 12 IN30154952932466 VIDHEESH TYAGI 21C VIJAY MANDAL ENCLAVE HAUZ KHAS DELHINEW DELHI NEW DELHI 110016 50 125 13 IN30154953043620 SIRSENDU BHOWMICK NC 07 IIT CAMPUS UDAIGIRINEW DELHI NEW DELHI 110016 150 375 14 IN30154951373040 OMEY SURESH PARIT RELIGARE HEALTH INSURANCE CO
    [Show full text]
  • Thyrocare Think Thyroid
    Thyrocare Think Thyroid. Think Thyrocare. July 31, 2019 The National Stock Exchange of India Limited The Bombay Stock Exchange Ltd Exchange Plaza Phiroze Jeejeeboy Towers Bandra Kurla Complex, Dalal Street, Bandra (E), Mumbai - 400 051 Mumbai- 400 001 Dear Sirs/Madam, Sub: Notice of 19th Annual General Meeting of our company. This is to inform you that the 19th Annual General Meeting of the Company will be held at 03.00 P.M. on Saturday, August 24, 2019, at Hotel Yogi Midtown, Plot No. DX-12, TIC Industrial Area, Mumbai-Pune Road, Turbhe, Navi Mumbai-400 705 to transact the ordinary and special business set out in the Notice of the meeting. In this regard, pursuant to the Regulation 34 (I) (a) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we are submitting herewith a copy of the Annual Report along with the Notice of the 19th Annual General Meeting, which is being sent to the Shareholders. We request you to kindly take the same on the record. Yours Faithfully, For Thyrocare Technologies Limited, Ramjee Dorai . Company Secretary and Compliance Officer Thyrocare Technologies Limited 9 D-37/1, TTC MIDC, Turbhe, Navi Mumbai -400 703, India � 022- 3090 0000 / 4125 2525 • [email protected] Cl) www.thyrocare com {CIN • l85110MH2000PLC123882 Annual Report 2018-19 Focussed. Committed. Tested. Contents Thyrocare – A Snapshot 02 Our Business Model 04 02-22 Our Business Segments 06 Corporate Delivering through Sound Strategy and Overview Strong Execution 08 Chairman’s Review 10 Focussed on Strengthening
    [Show full text]
  • Thyrocare Technologies Limited
    RED HERRING PROSPECTUS Dated April 11, 2016 (Please read Section 32 of the Companies Act, 2013) Book Built Issue THYROCARE TECHNOLOGIES LIMITED Our Company was incorporated as Thyrocare Technologies Limited on January 28, 2000 at Mumbai and received a certificate of commencement of business on March 7, 2000. It was incorporated as a public limited company under the Companies Act, 1956. For details, see the section entitled “History and Certain Corporate Matters” on page 151. Registered Office: D/37-1, TTC Industrial Area, MIDC Turbhe, Navi Mumbai 400 703; Tel: (91 22) 2762 2762; Fax: (91 22) 2768 2409 Contact Person: Ramjee Dorai, Company Secretary and Compliance Officer; E-mail: [email protected]; Website: www.thyrocare.com; Corporate Identity Number: U85110MH2000PLC123882 PROMOTERS OF OUR COMPANY: DR. A. VELUMANI AND A. SUNDARARAJU PUBLIC OFFER OF UP TO 10,744,708 EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH (THE “EQUITY SHARES”) OF THYROCARE TECHNOLOGIES LIMITED (OUR “COMPANY” OR THE “ISSUER”) FOR CASH, AT A PRICE OF ₹ [●] PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹ [●] PER EQUITY SHARE) THROUGH AN OFFER FOR SALE BY THE SELLING SHAREHOLDERS (AS DEFINED IN THE SECTION ENTITLED “DEFINITIONS AND ABBREVIATIONS” ON PAGE 1) AGGREGATING UP TO ₹ [●] MILLION (THE “OFFER”). FOR DETAILS OF THE EQUITY SHARES OFFERED BY EACH SELLING SHAREHOLDER, SEE THE SECTION ENTITLED “DEFINITIONS AND ABBREVIATIONS – OFFER RELATED TERMS – OFFER/OFFER FOR SALE” ON PAGE 6. THE FACE VALUE OF EQUITY SHARES IS ₹ 10 EACH. THE PRICE BAND AND THE MINIMUM BID LOT
    [Show full text]
  • COVID-19 Testing Labs in India
    भारतीय आयु셍वज्ञि ान अनुसंधान पररषद वा्य अनुसंधान 셍वभाग, वा्य और पररवार क쥍याण मंत्रालय, भारत सरकार Indian Council of Medical Research Department of Health Research, Ministry of Health and Family Welfare, Government of India Date: 11/06/2020 Total Operational (initiated independent testing) Laboratories reporting to ICMR: Government laboratories : 637 Private laboratories : 240 - Real-Time RT PCR for COVID-19 : 524 (Govt: 343 + Private: 181) - TrueNat Test for COVID-19 : 283 (Govt: 269 + Private: 14) - CBNAAT Test for COVID-19 : 70 (Govt: 25 + Private: 45) Total No. of Labs : 877 *CSIR/DBT/DST/DAE/ICAR/DRDO Laboratories. #Laboratories approved for both Real-Time RT-PCR and TrueNat/CBNAAT $Laboratories approved for both TrueNAT and CBNAAT S. Names of Test Names of Government Institutes Names of Private Institutes No. States Category 1. Andhra RT-PCR 1. Sri Venkateswara Institute of Medical 1. Manipal Hospital, Tadepalli, Guntur Pradesh (58) Sciences, Tirupati 2. PathGene Health Care Pvt Ltd#2nd Floor, 2. Sri Venkateswara Medical College, Srinivasapuram, Tiruchanoor Road, Opp LV Govt: 53 Tirupati kayanamandapam, Tirupathi 1 | P a g e S. Names of Test Names of Government Institutes Names of Private Institutes No. States Category Private: 5 3. Rangaraya Medical College, Kakinada 3. Apollo Health and Lifestyle Ltd, Vijayawada 4. #Sidhartha Medical College, Vijaywada Diagnostics Lab, 40-5-6, Parmeshwara 5. Govt. Medical College, Ananthpur Complex, Tikkle Road, Vijayawada 6. Guntur Medical College, Guntur 4. Vijaya Diagnostic Centre Pvt. Ltd., Plot No: 7. Rajiv Gandhi Institute of Medical 43/198, Old Rainbow Hospital Lane, N R Peta, Sciences, Kadapa Kurnool 8.
    [Show full text]
  • Thyrocare Technologies Limited Presentation – Q32021
    Thyrocare· Think Thyroid. Think Thyrocare. I February O 1, 2021 To, National Stock Exchange of India Limited SSE Limited Exchange Plaza Phiroze Jeejeeboy Towers Sandra Kurla Complex, Dalal Street, Sandra (E), Mumbai - 400 051 Mumbai- 400 00 I Dear Sirs, Sub: Presentation on Quarterly Results forthe quarter/ nine months ended 31-12-2020. --0-- We are forwarding a copy of Presentation on Quarterly Results of our company forthe quarter/ nine months ended 31-12-2020. Please note that this is only uploaded in our website, and has not been distributed or advertised in newspapers or otherwise publicised. Yours Faithfully, For Thyrocare Technologies Limited, Ramjee Dorai Company Secretary and Compliance Officer Thyrocare Technologies Limited 9 D-37/1, TTC MIDC, Turbhe, Navi Mumbai - 400 703, India @ 022- 3090 0000 / 4125 2525 � [email protected] (@ www.thyrocare.com (CIN: L85110MH2000PLC123882) Thyrocare Technologies Limited Presentation – Q32021 Disclaimer This presentation is for information purposes only and it contains general background information about the Company’s activities. The Company assumes no responsibility to publicly amend, modify or revise any forward looking statements on the basis of any subsequent development, information or events, or otherwise. This Presentation comprises information given in summary form and does not purport to be complete. This Presentation should not be considered as a recommendation to any investor to purchase the equity shares of the Company. This Presentation includes statements that are, or may be deemed to be, “forward-looking statements”. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future.
    [Show full text]
  • Dorai Ramjee
    FOR A HEALTHY AND PROSPEROUS INDIA ANNUAL REPORT 2019-20 Please find the online version of this report at http://investor.thyrocare.com/annual-report/ Corporate Statutory Financial Overview Reports Statements 01 10 92 Theme Introduction Board’s Report Standalone Financial Statements 02 39 147 Thyrocare: Pioneering Corporate Governance Consolidated Financial Contents Affordable and Accessible Report Statements Wellness and Preventive Care 04 58 205 Stepping up in Times Management Discussion 20th AGM Notice of Need and Analysis 06 83 Message from the Business Chairman Responsibility Report 08 Board of Directors 09 Corporate Information Revenue ` 400 Cr 8% FY 2019-20 EBITDA (normalised) Financial and Operational Highlights ` 168.41 Cr 9% Health crises have huge social and economic costs as witnessed in the recent COVID-19 pandemic. In PAT (normalised) India, however, healthcare has never been considered ` 112.08 Cr necessary until it is an emergency. It is estimated that 18% every 10% increase in noncommunicable diseases impacts annual economic growth rate by 0.5%. The rising healthcare costs and out-of-pocket expenditure, Free Cash Available along with increasing lifestyle-related diseases are ` 76.33 Cr further adding to the woes. At Thyrocare Technologies Limited (Thyrocare), we are strongly focussed on addressing this challenge Investigations by promoting preventive healthcare and making it Performed affordable and accessible to all. We have invested in a 11.04 Cr robust advanced technology-led laboratory that handles large sample volumes with highest accuracy, while 9% drastically reducing the costs, enabling us to provide tests at lowest prices. We have introduced innovative Samples test packages that enables individuals to undertake a Processed number of health check-ups at discounted prices.
    [Show full text]
  • Thyrocare Technologies Limited
    +91-8048372486 Thyrocare Technologies Limited https://www.indiamart.com/thyrocare-technologies-ltd-navi-mumbai/ Thyrocare Technologies Limited is India's first fully automated diagnostic laboratory with a focus on providing quality at affordable costs to laboratories and hospitals in India and other countries. About Us Thyrocare Technologies Limited is India's first fully automated diagnostic laboratory with a focus on providing quality at affordable costs to laboratories and hospitals in India and other countries.Thyrocare operates this unique centralised laboratory model with the focus on strong technologies, strong brands and strong systems that enable all laboratories to give their clients the best of science and technology at affordable costs.With a belief that 'Quality' is the heart of any intelligent management, Thyrocare became one the first Indian diagnostic laboratories to obtain internationally renowned quality accreditations like ISO 9001-2000 rating as early as 2001, which is now escalated to ISO 9001:2008; NABL (National Accreditation Board for Testing and Calibration Laboratories) in 2005 and CAP (College of American Pathologists) certification in 2006.Our clear focus on speed and accuracy further made us the first Indian laboratory to also have an IT enabled, 24x7, fully automated diagnostic laboratory set up covering over 1,20,000 sq. ft. floor space that ensures error free processing of over 30,000 samples in a night! Our unmatched speed factor is achieved through a combination of air-cargo logistics and IT enabled, barcoded, bi-directional systems that ensure a turnaround time of 4 to 8 hours for processing of samples that arrives at any time of the day or night.A meticulously created and monitored systems, well chosen and trained manpower, wise selection of the best..
    [Show full text]
  • Board's Report Report on CSR Activities
    THYROCARE TECHNOLOGIES LIMITED Board’s Report ANNEXURE-3 Report on CSR Activities 1 A brief outline of the company’s CSR policy, including The Company’s CSR Policy is based on the principle of extending overview of projects or programmes proposed to be support to the underprivileged segments of the Society and undertaken and a reference to the web-link to the rendering service to achieve selected goals for the common CSR policy and projects or programmes: benefit of the entire society. The Company has identified four thrust areas for implementation of its CSR Policy, viz. (i) Environment-oriented (ii) Society-oriented (iii) Education-oriented and (iv) Health-care oriented. CSR Policy may be viewed at the Company’s website, “www. thyrocare.com” 2 The composition of the CSR Committee: The Company has a CSR committee of directors comprising of - Mr. Gopalkrishna Shivaram Hegde, Independent Director- Chairman - Mr. Vishwas Kulkarni, Independent Director- Member - Mr. A. Sundararaju, Executive Director & CFO- Member ` in crores. 3 Average net profit of the Company for the three 135.23 financial years: 4 Prescribed CSR expenditure at 2% of the above 2.70 amount 5-a Total amount spent during the year 2019-20 4.09 5-b Amount unspent Does not arise. 5-c Manner in which the amount spent during the Mentioned in the Annexure attached. financial year 6 In case the company has failed to spend the two This does not apply for current year. There is a balance amount per cent of the average net profit of the last three relating to the earlier years, which could not be spent pending financial years or any part thereof, the company identification of suitable project(s), will be spent in the ensuing shall provide the reasons for not spending the financial years.
    [Show full text]